Free Access
Med Sci (Paris)
Volume 29, Number 11, Novembre 2013
Page(s) 998 - 1003
Section M/S Revues
Published online 20 November 2013
  1. Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009 ; 9 : 34. [CrossRef] [PubMed] [Google Scholar]
  2. Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010 ; 53 : 36–42. [CrossRef] [PubMed] [Google Scholar]
  3. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008 ; 48 : 148–162. [CrossRef] [PubMed] [Google Scholar]
  4. European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011 ; 55 : 245–64. [CrossRef] [PubMed] [Google Scholar]
  5. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002 ; 347 : 89–94. [CrossRef] [PubMed] [Google Scholar]
  6. Fontaine H, Chaix ML, Lagneau JL, et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000 ; 356 : 41. [CrossRef] [PubMed] [Google Scholar]
  7. Mchutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection. N Engl J Med 2009 ; 361 : 580–593. [CrossRef] [PubMed] [Google Scholar]
  8. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 ; 147 : 677–684. [CrossRef] [PubMed] [Google Scholar]
  9. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008 ; 149 : 399–403. [CrossRef] [PubMed] [Google Scholar]
  10. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012 ; 206 : 469–477. [CrossRef] [PubMed] [Google Scholar]
  11. Berenguer J, Rodríguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012 ; 55 : 728–736. [CrossRef] [PubMed] [Google Scholar]
  12. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007 ; 5 : 453–463. [CrossRef] [PubMed] [Google Scholar]
  13. Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012 ; 32 : 19–16. [CrossRef] [Google Scholar]
  14. Yang PL, Gao M, Lin K, et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011 ; 1 : 607–616. [CrossRef] [PubMed] [Google Scholar]
  15. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 ; 360 : 1839–1850. [CrossRef] [PubMed] [Google Scholar]
  16. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial. Lancet 2011 ; 376 : 705–716. [CrossRef] [Google Scholar]
  17. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010 ; 362 : 1292–1303. [CrossRef] [PubMed] [Google Scholar]
  18. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011 ; 364 : 2417–2428. [CrossRef] [PubMed] [Google Scholar]
  19. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011 ; 364 : 1207–1217. [Google Scholar]
  20. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011 ; 364 : 2405–2416. [CrossRef] [PubMed] [Google Scholar]
  21. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012 ; 56 : 455–463. [CrossRef] [PubMed] [Google Scholar]
  22. Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferonalfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS C020-CUPIC). 47th Meeting of the European association for the study of the liver. Barcelona: EASL, 2012 (abstract 8). [Google Scholar]
  23. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial. Lancet 2013 ; 381 : 2100–2107. [CrossRef] [PubMed] [Google Scholar]
  24. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010 ; 376 : 1467–1475. [CrossRef] [PubMed] [Google Scholar]
  25. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012 ; 12 : 671–677. [CrossRef] [PubMed] [Google Scholar]
  26. Zeuzem S, Asselah T, Angus PW, et al. Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011 ; 141 : 2047–2055. [CrossRef] [PubMed] [Google Scholar]
  27. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435–C202). J Hepatol 2013 ; 58 : 445–451. [CrossRef] [PubMed] [Google Scholar]
  28. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012 ; 366 : 216–224. [CrossRef] [PubMed] [Google Scholar]
  29. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013 ; 368 : 34–44. [CrossRef] [PubMed] [Google Scholar]
  30. Poordard F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013 ; 56 : S560. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.